Skip to main content
logo
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.390
+0.020 (1.46%)
At close: Mar 25, 2026, 4:00 PM EDT
1.400
+0.010 (0.72%)
After-hours: Mar 25, 2026, 5:26 PM EDT

Metagenomi Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
25.2152.344.7617.20.24
Revenue Growth (YoY)
-51.79%16.84%160.21%6978.19%-
Gross Profit
25.2152.344.7617.20.24
Selling, General & Admin
26.7932.0228.8518.79.71
Research & Development
94.43109.1894.443.1414.48
Total Operating Expenses
121.22141.2123.2561.8424.19
Operating Income
-96.01-88.9-78.49-44.64-23.95
Total Non-Operating Income (Expense)
8.095.3318.263.62-
Pretax Income
-87.93-83.57-60.23-41.02-21.44
Provision for Income Taxes
-0.06-5.518.032.57-
Net Income
-87.87-78.06-68.26-43.59-21.44
Net Income to Common
-87.87-78.06-68.26-43.59-21.44
Shares Outstanding (Basic)
3733333
Shares Outstanding (Diluted)
3733333
Shares Change (YoY)
12.79%870.10%0.15%-0.15%-
EPS (Basic)
-2.36-2.36-20.05-12.82-6.30
EPS (Diluted)
-2.36-2.36-20.05-12.82-6.30
Free Cash Flow
-89.47-112.19-101.2215.7521.35
Free Cash Flow Growth
----26.26%-
Free Cash Flow Per Share
-2.40-3.40-29.734.63-
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-380.85%-170.00%-175.38%-259.53%-9854.73%
Profit Margin
-348.54%-149.26%-152.50%-253.45%-8823.87%
FCF Margin
-354.88%-214.53%-226.17%91.55%8787.65%
EBITDA
-90.7-83.49-74.29-42.91-23.56
EBITDA Margin
-359.76%-159.66%-165.98%-249.46%-9695.47%
EBIT
-96.01-88.9-78.49-44.64-23.95
EBIT Margin
-380.85%-170.00%-175.38%-259.53%-9854.73%
Effective Tax Rate
0.07%6.60%-13.33%-6.26%0.00%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q